Reports of pulmonary hypertension in obese women treated with the appetite suppressant aminorex (Menocil) prompted this study using the calf as a model because of its very reactive pulmonary vascular bed. Acute and chronic haemodynamic effects were observed following daily intravenous injections of aminorex (0-25 mg/kg as free base) in four calves. Four other calves were similarly treated with the related sympathomimetic drug amphetamine in the same dose, and four calves served as controls. The acute effects of both these drugs were a significant increase in systemic arterial pressure and resistance with no change in pulmonary haemodynamics. The chronic effect of one month's treatment was to leave both systemic and pulmonary haemodynamics unchanged, and there was no depletion in endogenous catecholamines as measured by the tyramine test. In addition, the reactivity of the pulmonary vascular bed to hypoxia remained unaltered. Thus neither aminorex nor amphetamine produced pulmonary hypertension during one month's treatment in the calf.
Reports of pulmonary hypertension in obese women treated with the appetite suppressant aminorex (Menocil) prompted this study using the calf as a model because of its very reactive pulmonary vascular bed. Acute and chronic haemodynamic effects were observed following daily intravenous injections of aminorex (0-25 mg/kg as free base) in four calves. Four other calves were similarly treated with the related sympathomimetic drug amphetamine in the same dose, and four calves served as controls. The acute effects of both these drugs were a significant increase in systemic arterial pressure and resistance with no change in pulmonary haemodynamics. The chronic effect of one month's treatment was to leave both systemic and pulmonary haemodynamics unchanged, and there was no depletion in endogenous catecholamines as measured by the tyramine test. In addition, the reactivity of the pulmonary vascular bed to hypoxia remained unaltered. Thus neither aminorex nor amphetamine produced pulmonary hypertension during one month's treatment in the calf.
Aminorex (Menocil) is 2-amino-5-phenyl oxazoline and, like amphetamine, has a chemical structure similar to that of adrenaline (Fig. 1) . Both aminorex and amphetamine produce their pharmacological effects by releasing endogenous catecholamines, and both drugs suppress appetite (Poos et al., 1963; Chardonnens and Mahaim, 1969) . Because aminorex is an anorexigen, it came into widespread clinical use in 1965 for the treatment of obesity in Switzerland, western Germany, and Austria. Within a year, medical centres in those three countries began to report a striking increase in the incidence of primary pulmonary hypertension, and many of the patients were obese women who had taken aminorex (Gurtner et 1968; Kaindl, 1969; Rivier, 1970) . This circumstantial evidence gave rise to the suspicion that aminorex might have played an aetiological role in some of those cases of pulmonary hypertension. Except for substances which mechanically obstruct pulmonary blood vessels, e.g., emboli, few agents can produce sustained pulmonary hypertension. Of these, alveolar hypoxia is well known as a potent pulmonary vasoconstrictor. Chronic ingestion of the seeds of Crotolaria spectabilis, which contain monocrotaline, will produce severe pulmonary hypertension in animals and man (Kay and Heath, 1969) . However, no sympathomimetic drug has ever been shown to be capable of producing chronic pulmonary hypertension. There- Effects of aminorex and amphetamine on haemodynamics in the calf (PIo2=47 torr) and 4% C02 (PIc02=25 torr), balance N2, and all measurements were repeated when pulmonary artery pressure had stabilized, usually within 3 to 5 minutes. After 15 minutes' recovery, the usual daily dose of drug was given intravenously, pulmonary artery and aortic pressures were monitored continuously, and measurements of blood gases and cardiac output were again made after 3 minutes. On the final, 28th day, instead of being given the allocated drug, each surviving animal underwent a tyramine test to show whether or not catecholamine depletion had occurred (Gaffney, Morrow, and Chidsey, 1962 ). An intravenous injection of 0 1 mg/kg tyramine hydrochloride was given while the pulmonary artery pressure, aortic pressure, and heart rate were monitored. All variables measured were subjected to a threefactor analysis of variance (Scheffe, 1959) . (Table I) Before treatment, mean pulmonary arterial pressure (PPA) in all three groups of animals was within the range of normal for calves living at an altitude of 1,600 m (Reeves, Grover, Will, and Alexander, 1962) . By chance, the group selected to receive amphetamine had an initial PPA of 32-0 + 4 1 mmHg compared with 26 5 +±13 mmHg in the control group and 26-3 +1 0 mmHg in the group destined to receive aminorex. Daily treatment for one month produced a slight but non-significant increase in PPA in all three groups (Fig. 2) . It is Thus, pulmonary hypertension did not result from the chronic administration of aminorex or amphetamine (or saline). Neither was there a significant increase in total pulmonary resistance (TPR) in any of the three groups.
RESULTS

PULMONARY HAEMODYkNAMICS
Acute hypoxia lowered Pao2 from 65 torr to 30 torr and produced hyperventilation. However, the presence of 4% CO2 in the inspired hypoxic gas mixture prevented hypocapnia and thus avoided the development of alkalosis which might have attenuated the pulmonary pressor response (Ferrer, Enson, and Harvey, 1969) . Consequently, acute hypoxia produced a rise in PPA (Fig. 3) noteworthy that after daily injections of aminorex for one month, PPA was 31-7 + 1-9 mmHg, which is no higher than the initial pressures of 320+441
The acute response to the injection of 6 ml of saline into the pulmonary artery was a variable and non-significant rise in PPA of 2-4 mmHg. group.bmj.com on April 14, 2017 -Published by http://thorax.bmj.com/ Downloaded from Neither aminorex nor amphetamine produced a rise in PPA any greater than this. Thus, while these drugs did produce a transient systemic pressure rise, they had no acute pulmonary pressor effect (Fig. 4) . SYSTEMIC HAEMODYNAMICS (Table II Thus, the daily administration of sympathomimetic drugs did not produce sustained systemic hypertension. In addition, after 28 days of treatment the responses to tyramine indicated that the endogenous stores of catecholamines had not been depleted. In each of the three groups, tyramine produced a significant rise in aortic pressure and a reflex decrease in heart rate.
During acute hypoxia, there was a marked tachycardia, an increase in cardiac output, and a decrease in TSR. This pattern of response did not change during the one month of study.
Body weight did not change significantly in any of the three groups of calves during the course of this investigation. Thus, the effects on weight of the daily administration of appetite suppressants were similar to the effects of a daily injection of saline.
COMPLICATIONS On the 23rd day, one animal in the amphetamine group died, and on the 25th day one animal in the aminorex group also died. In both animals, death was preceded by tachycardia, fever, and dyspnoea. We suspected that there was sepsis and pulmonary infarction due to the indwelling pulmonary artery catheters, and this was confirmed at necropsy which also showed that the catheters were extensively coated with fibrin. One of the control animals developed similar symptoms the day after the study concluded and was therefore sacrificed; the necropsy changes resembled those found in the other two. These complications did not cause pulmonary hypertension in any of the three calves.
DISCUSSION
The calf (bas taurus) was considered to be the ideal experimental animal for this investigation. This species has a remarkably reactive pulmonary vascular bed and will develop severe pulmonary hypertension when exposed to the stimulus of chronic atmospheric hypoxia (PI02 90 torr). The milder degree of atmospheric hypoxia (PI02 120 torr) which exists in Denver (PB 625 torr) will not in itself produce pulmonary hypertension but will potentiate the effects of other stimuli. Thus, an increase in pulmonary blood flow through the left lung (produced by ligation of the right pulmonary artery) leads to the development of pulmonary hypertension in Denver, but not at sea level where mild hypoxia is absent (Vogel et al., 1967) . Furthermore, we have shown that norepinephrine will increase pulmonary vascular resistance in the calf lung perfused at constant flow in situ (Silove, Inoue, and Grover, 1968) .
Effects of aminorex and amphetamine on haemodynamics in the cal1
The calves studied during the present investigation had pulmonary vascular beds capable of marked vasoconstriction. Acute hypoxia doubled the total pulmonary vascular resistance and increased PPA to 40-40 mmHg. In contrast, PPA increased only 2-4 mmHg following the injection of either aminorex or amphetamine, and this is no greater than the acute response to 6 ml of saline alone. Consistent with this negative acute response was the absence of significant pulmonary hypertension following the chronic administration of these sympathomimetic drugs. However, in the aminorex group there was an upward trend in total pulmonary resistance (TPR) during normoxia and hypoxia over the 28 days. This trend did not achieve statistical significance in either case and none of the values was outside the normal range. It should be emphasized that TPR is not a very precise derivation, particularly during acute hypoxia in the calf.
These negative results with regard to the pulmonary circulation cannot be attributed to an ineffective dosage. Shortly after the injection of either aminorex or amphetamine, there was a transient sharp rise in systemic arterial pressure due to an increase in systemic vascular resistance, indicating the acute release of endogenous catecholamines. Tyramine had a similar effect. The dosage employed for aminorex, 0 25 mg/kg, was approximately twice the human therapeutic dose.
A transient small increase in pulmonary artery pressure has been reported in dogs given intravenous aminorex, 10-160 mg/kg (Kraupp, Stuhlinger, Raberger, and Turnheim, 1969) . However, Will and Bisgard (1971) have recently shown that pure-bred beagle dogs, receiving either aminorex or amphetamine orally in doses of 1 5 mg/kg (sixfold greater than in the present study) for four days, failed to develop pulmonary hypertension. Chronic administration of aminorex to rats has also failed to produce any evidence of pulmonary hypertension (Kay, Smith and Heath, 1971) .
This investigation has shown that neither aminorex nor amphetamine will produce pulmonary hypertension in the calf and indeed these sympathomimetic agents have not produced pulmonary hypertension in any experimental animal thus far tested. We must therefore conclude that neither aminorex nor amphetamine is an effective agent for the deliberate induction of experimental pulmonary hypertension. However, caution should be used in extrapolating the results of this study to man. 
